english.prescrire.org > Spotlight > 100 most recent > GLP-1 agonists: depression, suicidal thoughts or behaviour?


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

GLP-1 agonists: depression, suicidal thoughts or behaviour?

 Adverse effects   In July 2023, the European pharmacovigilance committee (PRAC) decided to launch a review of GLP-1 agonists, following reports of suicidal thoughts and thoughts of self-harm. To what extent do GLP-1 agonists expose patients to a risk of depression, suicidal ideation, attempted suicide or suicide? This article summarises the main findings of our search of the literature for answers to this question.
Full article available for download by subscribers

©Prescrire 1 April 2024

Source: "GLP-1 agonists: depression, suicidal thoughts or behaviour?" Prescrire Int 2024; 33 (258): 103-105. Subscribers only.

Enjoy full access to Prescrire International, and support independent information


Share on  Facebook Share on  Twitter

Subscribe now

See also:

"Prescrire Editorial Staff
"Liraglutide (Saxenda°)
in obesity in adolescents""
Prescrire Int 2022;
31 (242): 260-261.
Subscribers only

Read more:

This month's contents

All the subjects in
Prescrire's spotlight